文献速递前列腺癌

美国首个经会阴靶向前列腺穿刺平台的初步系列研究

Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA.
PubMed 文献 · BJU Int · 2018-04-14

该研究描述了美国首个经会阴靶向前列腺穿刺平台的操作步骤,纳入32例PSA升高且mpMRI有感兴趣区的男性,行经会阴靶向穿刺。总体前列腺癌检出率为81%,临床显著前列腺癌检出率为59%,无围手术期并发症。

要点

  • 经会阴靶向穿刺平台在美国首次应用,总体前列腺癌检出率81%。
  • 临床显著前列腺癌检出率59%,无围手术期并发症。
  • 既往穿刺阴性者中8例经靶向穿刺确诊临床显著前列腺癌。

核心结论

  • 美国首个经会阴靶向前列腺穿刺平台作为前列腺癌替代诊断方法具有良好潜力。

研究设计与样本

  • 2017年2月至2018年1月纳入32例PSA升高且mpMRI发现感兴趣区的男性,行经会阴靶向穿刺。

主要发现

  • 中位年龄68.0岁,中位PSA 8.0 ng/mL。
  • 总体前列腺癌检出率为81%,临床显著前列腺癌检出率为59%。
  • 2例(6%)为主动监测候选者,16例(50%)既往前列腺穿刺阴性。
  • 2例主动监测候选者及8例既往穿刺阴性者经靶向穿刺确诊临床显著前列腺癌。
  • 无围手术期并发症。

临床怎么用

  • 经会阴靶向穿刺平台可作为前列腺癌诊断的替代方法,尤其适用于既往穿刺阴性且mpMRI有感兴趣区者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. PATIENTS AND METHODS: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. RESULTS: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. CONCLUSION: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kosarek CD, Mahmoud AM, Eyzaguirre EJ, et al. Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA. BJU Int. 2018. PMID: 29569311. doi:10.1111/bju.14206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。